Sugi Predict

Sugi Predict / Compounds / SCHEMBL2483166

SCHEMBL2483166

SCHEMBL2483166

Cc1cccc(NC(N)=S)n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.72
▸ MEN1 O00255 4/20 0.72
▸ RAB9A P51151 5/20 0.61
▸ GRM5 P41594 2/20 0.54
▸ ALDH1A1 P00352 4/20 0.54
▸ CACNA1B Q00975 3/20 0.54
▸ APBA1 Q02410 3/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ NPSR1 Q6W5P4 2/20 0.53
▸ NPC1 O15118 4/20 0.51
▸ GBA1 P04062 2/20 0.51
▸ LMNA P02545 3/20 0.51
▸ KDM4E B2RXH2 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30070833 1.00 KMT2A (0.72) KMT2AMEN1RAB9AGRM5ALDH1A1
SCHEMBL11524092 0.85 KMT2A (0.68) KMT2AMEN1RAB9AGRM5ALDH1A1
SCHEMBL5034141 0.81 RAB9A (0.72) KMT2AMEN1RAB9AGRM5NPC1
SCHEMBL30509648 0.81 RAB9A (0.72) KMT2AMEN1RAB9AGRM5NPC1
SCHEMBL11524091 0.81 KMT2A (0.72) KMT2AMEN1RAB9AGRM5ALDH1A1
SCHEMBL4327363 0.79 KMT2A (0.74) KMT2AMEN1RAB9AGRM5ALDH1A1
SCHEMBL4557665 0.79 RAB9A (0.58) KMT2AMEN1RAB9AGRM5NPSR1
SCHEMBL2483314 0.77 KMT2A (0.43) KMT2AMEN1ALDH1A1HTTNPSR1
SCHEMBL14758347 0.77 KMT2A (0.43) KMT2AMEN1GRM5ALDH1A1NPSR1
SCHEMBL2780923 0.77 L3MBTL1 (0.44) KMT2AMEN1GRM5ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115466254-A Inhibitor and preparation method thereof 安庆研至医药科技有限公司 2022-12-13 — — CN claimed
EP-4725470-A1 CURABLE DENTAL COMPOSITION Kuraray Noritake Dental Inc. (JP) 2026-04-15 — — EP disclosed
US-20250032366-A1 DENTAL CURABLE COMPOSITION KURARAY NORITAKE DENTAL INC. (JP) 2025-01-30 — — US disclosed
WO-2024253204-A1 CURABLE DENTAL COMPOSITION クラレノリタケデンタル株式会社 2024-12-12 — — WO disclosed
EP-4445891-A1 DENTAL CURABLE COMPOSITION Kuraray Noritake Dental Inc. (JP) 2024-10-16 — — EP disclosed
CN-118338879-A Curable composition for dental use 可乐丽则武齿科株式会社 2024-07-12 — — CN disclosed
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof Ikena Oncology, Inc. (US) 2024-07-09 — — US disclosed
US-20230295147-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF ARYL THERAPEUTICS, INC. 2023-09-21 — — US disclosed
WO-2023106419-A1 DENTAL CURABLE COMPOSITION クラレノリタケデンタル株式会社 2023-06-15 — — WO disclosed
CN-115466254-A Inhibitor and preparation method thereof 安庆研至医药科技有限公司 2022-12-13 — — CN disclosed
EP-1339711-A1 AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS Novartis AG (CH) 2003-09-03 — — EP disclosed
US-6586424-B2 Anticancer agents; anticholesterol agents MERCK & CO., INC. 2003-07-01 — — US disclosed
US-6586423-B2 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy MERCK & CO., INC. 2003-07-01 — — US disclosed
US-20030064996-A1 Tyrosine kinase inhibitors MERCK SHARP & DOHME CORP. 2003-04-03 — — US disclosed
CN-1390215-A Tyrosine kinase inhibitors MERCK & CO INC (US) 2003-01-08 — — CN disclosed
EP-1218376-A4 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2002-11-20 — — EP disclosed
US-20020147203-A1 Tyrosine kinase inhibitors MERCK & CO., INC. 2002-10-10 — — US disclosed
EP-1218376-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2002-07-03 — — EP disclosed
WO-2002042298-A1 AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2002-05-30 — — WO disclosed
WO-2001017995-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2001-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147203-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 KMT2A 3298/4885MEN1 4406/4885RAB9A 2382/4885
US-20250032366-A1 DENTAL CURABLE COMPOSITION H1-0, COL1A1, CHAF1B KMT2A 2851/4885MEN1 353/4885RAB9A 3034/4885
US-12030876-B2 Aryl hydrocarbon receptor (AHR) agonists and uses thereof AHR, ARNT, HCAR1 KMT2A 1031/4885MEN1 4851/4885RAB9A 4470/4885
US-20230295147-A1 ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF AHR, ARNT, HCAR1 KMT2A 1031/4885MEN1 4851/4885RAB9A 4470/4885
US-20030064996-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 KMT2A 3298/4885MEN1 4406/4885RAB9A 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.